Tianjin Pharmaceutical Da Ren Tang (SGX:T14, SHA:600329) will inject 493.6 million yuan into Tianjin Pharmaceutical Group Taiping Medicine, according to a Wednesday filing on the Singapore Exchange.
The capital injection will be carried out through the transfer of Tianjin Pharmaceutical Da Ren Tang's 100% equity interest in Tianjin Zhongxin Medicine to Tianjin Pharmaceutical Group Taiping Medicine.
This move will create a joint venture with Tianjin Pharmaceutical Holdings, which will hold a 56.7% stake in Tianjin Pharmaceutical Group Taiping Medicine.
Price (SGD): S$2.05, Change: S$+0.020, Percent Change: +0.99%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。